IL4 and atopic eczema: The role of these cytokines in the pathophysiology of atopic dermatitis is supported by the response to dupilumab, which interrupts IL-4 signalling, and Janus kinase (JAK) inhibitors, which result in the inhibition of IL-4 receptors [32].